Back


22/09/2017
Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus
Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has completed the recruitment [...]




X

X